A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses

Molecular Psychiatry

Volumn 9, Issue 12, 2004, Pages 1067-1074

  Chagnon, Yvon C ^a   Merette C ^a   Bouchard, R H ^a   Emond C ^a   Roy, M A ^a   Maziade, M ^a  

^a CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

Bipolar disorder; Melanin concentrating hormone; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CHLORPROTHIXENE; FLUPHENAZINE; HALOPERIDOL; HORMONE PRECURSOR; LEVOMEPROMAZINE; LITHIUM; MELANIN CONCENTRATING HORMONE; NEUROLEPTIC AGENT; PERPHENAZINE; PIPOTIAZINE; PROMELANIN CONCENTRATING HORMONE; PROMETHAZINE; RISPERIDONE; THIOPROPERAZINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; BIPOLAR DISORDER; BODY WEIGHT; CANADA; CHROMOSOME 12Q; DEPRESSION; ENERGY EXPENDITURE; FAMILY STUDY; FOOD INTAKE; GENE; GENETIC LINKAGE; HUMAN; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHLORPROMAZINE; CHROMOSOMES, HUMAN, PAIR 12; COMORBIDITY; GENETIC PREDISPOSITION TO DISEASE; HALOPERIDOL; HUMANS; HYPOTHALAMIC HORMONES; LINKAGE (GENETICS); LOD SCORE; MODELS, GENETIC; OBESITY; PEDIGREE; PROTEIN PRECURSORS; PSYCHOTIC DISORDERS; QUEBEC; SCHIZOPHRENIA;

EID: 11244270333     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001537     Document Type: Article

References (45)

1. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21: 463-472.
2. National Heart, Lung, and Blood Institute. Obesity Education Initiative: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. US Department of Health and Human Services, 1998.
3. Falloon I, Watt DC, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 1978; 8: 59-70.
4. Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001; 62(Suppl 2): 41-44.
5. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
6. Bouchard RH, Demers MF, Simoneau I, Almeras N, Villeneuve J, Mottard JP et al. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin Psychopharmacol 2001; 21: 110-111.
7. Stunkard AJ. Genetic contributions to human obesity. Res Publ Assoc Res Nerv Ment Dis 1991; 69: 205-218.
8. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96.
9. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29-39.
10. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001; 24: 59-73.
11. Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 1998; 4: 1152-1156.
12. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000; 43: 373-376.
13. Aubert R, Betoulle D, Herbeth B, Siest G, Fumeron F. 5-HT2A receptor gene polymorphism is associated with food and alcohol intake in obese people. Int J Obes Relat Metab Disord 2000; 24: 920-924.
14. Levitan RD, Kaplan AS, Masellis M, Basile VS, Walker ML, Lipson N et al. Polymorphism of the serotonin 5-HT1B receptor gene (HTR1B) associated with minimum lifetime body mass index in women with bulimia nervosa. Biol Psychiatry 2001; 50: 640-643.
15. Rietschel M, Naber D, Fimmers R, Moller HJ, Propping P, Nothen MM. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1997; 8: 1999-2003.
16. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086-2087.
17. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295.
18. Ellingrod VL, Miller D, Schultz SK, Wehring H, Arndt S. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet 2002; 12: 55-58.
19. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62(Suppl 23): 45-66.
20. Reynolds GP, Yao Z, Zhang Z. Genetic factors associated with antipsychotic drug-induced weight gain-leptin and 5-HT2C receptor promoter polymorphisms. In: Malhotra AK (ed). Pharmacogenetics in Psychiatry. North Shore-Long Island Jewish Health System: New York, 2003.
21. Maziade M, Fournier A, Phaneuf D, Cliche D, Fournier JP, Roy MA et al. Chromosome 1q12-q22 linkage results in eastern Quebec families affected by schizophrenia. Am J Med Genet 2002; 114: 51-55.
22. Maziade M, Roy MA, Rouillard E, Bissonnette L, Fournier JP, Roy A et al. A search for specific and common susceptibility loci for schizophrenia and bipolar disorder: a linkage study in 13 target chromosomes. Mol Psychiatry 2001; 6: 684-693.
23. Maziade M, Roy M-A, Fournier J-P, Cliche D, Mérette C, Caron C et al. Reliability of best-estimate diagnosis in genetic linkage studies of major psychoses. Results from the Québec pedigrees studies. Am J Psychiatry 1992; 149: 1674-1686.
24. Maziade M, Roy M-A, Martinez M, Cliche D, Fournier J-P, Garneau Y et al. Negative, psychoticism, and the disorganized dimensions in patients with familial schizophrenia or bipolar disorder: continuity or discontinuity between the major psychoses. Am J Psychiatry 1995; 152: 1458-1463.
25. Chagnon Y, Roy S, Chagnon M, Lacaille M, Leblanc C, Bouchard C. High-throughput Genotyping Using Infrared Automatic LI-COR DNA Sequencers in the Study of the Obesity and Co-morbidities Genes. LiCor: Lincoln, Nebraska, USA, 1998 p. 5.
26. O'Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet 1998; 63: 259-266.
27. Durner M, Vieland VJ, Greenberg DA. Further evidence for the increased power of LOD scores compared with nonparametric methods. Am J Hum Genet 1999; 64: 281-289.
28. Abreu PC, Greenberg DA, Hodge SE. Direct power comparisons between simple LOD scores and NPL scores for linkage analysis in complex diseases. Am J Hum Genet 1999; 65: 847-857.
29. Vieland VJ, Greenberg DA, Hodge SE. Adequacy of single-locus approximations for linkage analyses of oligogenic traits: extension to multigenerational pedigree structures. Hum Hered 1993; 43: 329-336.
30. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995; 11: 241-247.
31. Hodge SE, Abreu PC, Greenberg DA. Magnitude of type I error when single-locus linkage analysis is maximized over models: a simulation study. Am J Hum Genet 1997; 60: 217-227.
32. Rao DC, Province MA. The future of path analysis, segregation analysis, and combined models for genetic dissection of complex traits. Hum Hered 2000; 50: 34-42.
33. Ott J. Computer-simulation methods in human linkage analysis. Proc Natl Acad Sci USA 1989; 86: 4175-4178.
34. Martinez M, Khlat M, Leboyer M, Clerget-Darpoux F. Performance of linkage analysis under misclassification error when the genetic model is unknown. Genet Epidemiol 1989; 6: 253-258.
35. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996; 380: 243-247.
36. Ludwig DS, Tritos NA, Mastaitis JW, Kulkarni R, Kokkotou E, Elmquist J et al. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 2001; 107: 379-386.
37. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998; 396: 670-674.
38. Marsh DJ, Weingarth DT, Novi DE, Chen HY, Trumbauer ME, Chen AS et al. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA 2002; 99: 3240-3245.
39. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 2002; 8: 825-830.
40. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003; 160: 677-679.
41. Dong GZ, Kameyama K, Rinken A, Haga T. Ligand binding properties of muscarinic acetylcholine receptor subtypes (m1-m5) expressed in baculovirus-infected insect cells. J Pharmacol Exp Ther 1995; 274: 378-384.
42. Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, Makita R et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001; 410: 207-212.
43. Gutierrez R, Tellez LA, Bermudez-Rattoni F. Blockade of cortical muscarinic but not NMDA receptors prevents a novel taste from becoming familiar. Eur J Neurosci 2003; 17: 1556-1562.
44. Pollmacher T, Schuld A, Kraus T, Haack M, Hinze-Selch D. On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors]. Fortschr Neural Psychiatr 2001; 69(Suppl 2): S65-S74.
45. Warne JP. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J Endocrinol 2003; 177: 351-355.